secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-281988
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q3 JELMYTO revenue up 41% to $16.1M; net loss narrows to $25.8M
----------------------------------------------------------------------

- JELMYTO net product revenue $16.1M (+41% YoY); operating loss improved to $18.1M from $23.4M.
- Net loss $25.8M ($1.13/share) vs $30.2M ($1.35/share) in Q3 2021; cash, cash equivalents and marketable securities $95.9M.
- ENVISION Phase 3 trial for UGN-102 enrollment completion expected as soon as end of Nov 2022; NDA submission anticipated H1 2024.
- FDA authorized extension of JELMYTO in-use period from 8 to 96 hours following reconstitution.
- Appointed Dr. Leana S. Wen and Dan Wildman to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522281988/0001193125-22-281988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522281988/d405971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer